

GENERAL ANNOUNCEMENT::RESEARCH COLLABORATION AGREEMENT WITH THE INSTITUTE OF CHEMICAL AND ENGINEERING SCIENCES

Issuer & Securities

Issuer/ Manager

HYPHENS PHARMA INTERNATIONAL LIMITED

Securities

HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5

Stapled Security

No

Announcement Details

Announcement Title

General Announcement

Date & Time of Broadcast

17-Dec-2019 17:16:12

Status

New

Announcement Sub Title

Research Collaboration Agreement with the Institute of Chemical and Engineering Sciences

Announcement Reference

SG191217OTHR5PHA

Submitted By (Co./ Ind. Name)

Lim See Wah

Designation

Executive Chairman and CEO

Description (Please provide a detailed description of the event in the box below)

Please refer to the press release.

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the Rules of Catalist. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no

responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.

Attachments

[HPIL Press-Release RCA.pdf](#)

Total size =411K MB

Media Release

Hyphens Pharma inks Research Collaboration Agreement with the Institute of Chemical and Engineering Sciences

Singapore, 17 December 2019 – Hyphens Pharma Pte Ltd (“**Hyphens Pharma**”), a wholly-owned subsidiary company of Hyphens Pharma International Limited (“**凯帆药剂国际有限公司**”), Singapore’s leading specialty pharmaceutical and consumer healthcare group, has entered into a Research Collaboration Agreement (“**RCA**”) with A*STAR’s Institute of Chemical and Engineering Sciences (“**ICES**”) to research and develop a new formulation for hand cream application.

The new formulation for hand cream application will be built on the foundation of Hyphens Pharma’s latest product, **Ceradan® Advanced**, a patent - pending emollient with a skin pH buffering system built - in to maintain skin barrier integrity for longer periods of time.

Ms Ng Sue Phay, Senior Manager, Product Development of Hyphens Pharma commented: “We are pleased to extend the platform technology used in **Ceradan® Advanced** to formulate a new hand cream which caters specifically to patients with hand eczema. Such R&D will in part help to add value to our **Ceradan®** products in the medical and consumer market.”

Hand eczema, also known as hand dermatitis, is a common condition that affects about 10% of the general population and is usually triggered by both genetics and contact allergens, as well as substances that will cause irritation. Affected patients includes personnel working in industries such as cleaning, catering, hairdressing, healthcare and mechanical, where they may come into contact with chemicals and other irritants. ¹

End.

¹ <https://nationaleczema.org/eczema/types-of-eczema/hand-eczema/>

About Hyphens Pharma International Limited

(<https://www.hyphensgroup.com>)

Hyphens Pharma International Limited and its subsidiaries (the "Group") is Singapore's leading specialty pharmaceutical and consumer healthcare group leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in Singapore, Vietnam, Malaysia, Indonesia and the Philippines, and is supplemented by a marketing and distribution network covering six additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia, Oman and Bangladesh.

Singapore is the Group's regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based. The Group's core business comprises the following segments: Specialty Pharma Principals, Proprietary Brands, and Medical Hypermart and Digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

Issued on behalf of the Company by Cogent Communications Pte Ltd.
For enquiries, please contact:

Ms Candy Soh, Tel: (65) 6704-9284, Mob: (65) 9816-8391
Email: candysoh@kogentcomms.com

Mr Gerald Woon, Tel: (65) 6704-9268, Mob: (65) 9694-8364
Email: woon@kogentcomms.com

This press release has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the Rules of Catalyst. The Sponsor has not independently verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact persons for the Sponsor are Ms Heng Mui Mui, Managing Director, and Mr Kelvin Wong, Vice President, who can be contacted at 12 Marina Boulevard, Level 46, Marina Bay Financial Centre Tower 3, Singapore 018982, Telephone: +65 6878 8888.